Individualised HbA1c Target

The number to treat towards, why it is not the normal value, and where the guidelines disagree · v1

  • Enter the type of diabetes, the age, the duration, the current treatment, and the patient's health status; the current HbA1c is optional.
  • Tick the hypoglycaemia history, the comorbidities and complications, and anything that makes the HbA1c itself unreliable.
  • You get an individualised HbA1c target with the reason for it, drawn on a scale beside the normal range so that the two are not confused.
  • The seven wedges under the scale show where this patient sits on each of the factors the ADA and EASD framework uses, which is the argument behind the number.
  • Where guidelines disagree, both figures are printed and neither is chosen for you.

  • Children and adolescents under 18. Their targets sit in the ISPAD guidance, which was not built into this tool.
  • The choice of drug, or a dose. The outpatient diabetes pathway and the inpatient insulin tool do that; this one sets the number those tools work towards.
  • An HbA1c target for gestational diabetes. No guideline read for this tool gives one; glucose targets are printed instead.
  • A numeric target for a patient in very poor health or at the end of life. The guidelines withhold one deliberately, and so does the tool.
  • Inpatient glucose targets. The ward and intensive care ranges are a different question.

1. The Patient

This field governs the rest of the form. Gestational diabetes goes straight to the pregnancy targets and asks nothing about duration or comorbidity.
Adults only. Below 18 the tool declares itself out of scope and stops.
Pregnancy changes the target and also changes what the HbA1c means, so it comes before the other questions.
Years since diagnosis. Enter 0 for a diagnosis made this year.
Optional. With it, the tool marks where the patient is against the target and says whether the treatment is under- or over-shooting.
Optional. Below 60 the KDIGO range applies; below 30 the HbA1c itself becomes unreliable.

2. Treatment and Hypoglycaemia

Hypoglycaemia belongs to the drug, not to the diabetes. Only insulin, sulfonylureas and meglitinides carry a meaningful risk, and the questions that follow appear only for them.
The first three are the major risk factors in the ADA table; any one of them on insulin or a sulfonylurea is an absolute reason to set a higher target. The others count together.

3. Health Status and Life Expectancy

These are the three ADA categories, and they decide the starting point. Instrumental activities are shopping, cooking, managing money and medicines; basic activities are bathing, dressing, feeding, toileting and transfers.
Ticked, this places the patient in the very complex category whatever was chosen above. A microvascular benefit takes years to arrive.

4. Comorbidities and Established Complications

Established vascular disease is the wedge the trials were about. The three cardiovascular trials that showed no benefit from near-normal control enrolled patients like these, eight to eleven years into the illness.

5. What the Patient Brings

The two wedges the framework calls potentially modifiable. They move the target only when the treatment is one that can cause hypoglycaemia, and the tool says why.

6. Can This HbA1c Be Trusted?

Iron deficiency pushes the HbA1c up; everything that shortens the red cell's life pushes it down. Pregnancy and advanced kidney disease are read from the fields above and need no tick.

1. A Normal HbA1c and a Target HbA1c Are Different Numbers

Both the ADA and the ICMR draw the same three bands: normal below 5.7 per cent, prediabetes 5.7 to 6.4, diabetes at 6.5 and above. For most adults the treatment target is 7.0, which sits above the diabetic threshold, and the gap is deliberate. The target is set where the benefit of lowering glucose is still large and the cost of getting there with drugs is still small.

  • The benefit side. UKPDS took newly diagnosed type 2 patients from 7.9 to 7.0 per cent and cut microvascular endpoints by 25 per cent. DCCT took type 1 patients from about 9 to about 7 and cut retinopathy, neuropathy and kidney disease by 50 to 76 per cent.
  • The cost side. ACCORD took a high-risk type 2 population with a median duration of 10 years towards normal, reaching 6.4 per cent against 7.5, and mortality rose (hazard ratio 1.22, 95 per cent CI 1.01 to 1.46). The trial was stopped at 3.5 years.
  • The shape of the curve. The ADA reads DCCT and UKPDS as curvilinear: most complications are prevented by moving from very high to about 7, and the further step from 7 to 6 adds a much smaller absolute gain that hypoglycaemia can outweigh on insulin or a sulfonylurea.

2. The Seven Factors, and Which of Them Can Be Changed

Ismail-Beigi and colleagues proposed the framework in 2011 and the ADA and EASD position statement of 2012, updated in 2015, drew it as seven wedges. Five are usually fixed for a given patient and two can be worked on.

FactorMoves the target tighterMoves the target looser
Risks from hypoglycaemia and other adverse effectsLow: lifestyle or agents that do not cause hypoglycaemiaHigh: insulin or a sulfonylurea with a recent severe episode or impaired awareness
Disease durationNewly diagnosedLong-standing
Life expectancyLongShort
Important comorbiditiesAbsentSevere
Established vascular complicationsAbsentSevere
Attitude and expected treatment effortMotivated, adherent, good self-careLess motivated, non-adherent, poor self-care
Resources and support systemReadily availableLimited

The 2026 ADA figure keeps the same factors but starts from health status: a healthy adult begins at 7.0, a complex one at 8.0, and a very complex one has no HbA1c target at all. This tool follows that order and then applies the wedges as modifiers.

3. What the Cardiovascular Trials Did and Did Not Show

TrialPopulationHbA1c reachedResult
UKPDS 33, 19983867 newly diagnosed type 2, median age 547.0 vs 7.9Any diabetes endpoint down 12 per cent; microvascular down 25; no macrovascular effect in the trial
UKPDS 80 and 91, 2008 and 2024The same cohort followed to 24 years after the trialDifference lost within a yearDeath down 10 per cent, myocardial infarction down 17, microvascular down 26; no waning
ACCORD, 200810,251 type 2 with CVD or risk factors, mean age 626.4 vs 7.5Death up (HR 1.22); stopped at 3.5 years
ADVANCE, 200811,140 type 2, gliclazide-based6.5 vs 7.3Nephropathy down 21 per cent; no cardiovascular or mortality effect; severe hypoglycaemia 2.7 vs 1.5 per cent
VADT, 2009 and 20191791 veterans, mean duration 11.5 years6.9 vs 8.4No cardiovascular benefit; hypoglycaemia 24.1 vs 17.6 per cent; no legacy effect at 15 years
DCCT/EDIC, 1993 and 20161441 type 1About 7 vs about 9Any cardiovascular disease down 30 per cent at 30 years; the lower HbA1c accounts for all of it

Two readings follow. Early, near-normal control in a new diagnosis pays for decades. Late, near-normal control in an established, high-risk patient on insulin and secretagogues has not paid, and in ACCORD it cost lives. The ACCORD hypoglycaemia analysis found that severe hypoglycaemia raised mortality in both arms but did not by itself explain the difference between them, so the harm is not fully understood. None of these trials used an SGLT2 inhibitor or a GLP-1 receptor agonist, whose cardiovascular benefit is independent of the HbA1c.

4. Where the Guidelines Disagree

QuestionADA 2026NICE 2026Others
Type 2 on lifestyle or metformin aloneBelow 7.0; below 6.5 may be appropriate6.5ICMR 2018 and RSSDI 2022: below 7.0
Type 2 on a drug that causes hypoglycaemiaBelow 7.07.0; intensify at 7.5ACP 2018: 7.0 to 8.0 for most; de-intensify below 6.5
Type 1 adultsBelow 7.06.5 or lower, without problematic hypoglycaemiaDCCT reached about 7
Diabetes with CKD, not on dialysisAs for health statusAs aboveKDIGO 2022: an individualised range from below 6.5 to below 8.0
Fasting glucose in pregnancyBelow 95Not compared hereMoHFW 2018: below 95; ICMR 2018: below 90
Fasting glucose outside pregnancy80 to 130; peak post-prandial below 180Not statedICMR 2018: 80 to 110; 2-hour 120 to 140

5. The HbA1c Is a Red Cell Measurement Before It Is a Glucose Measurement

Glycation accumulates over the life of the red cell, so anything that changes that life changes the number without changing the glucose.

  • Iron deficiency raises it. In 75 non-diabetic adults with iron deficiency anaemia in Chennai the HbA1c was 6.84 per cent against 5.12 in controls, and it rose with the severity of the anaemia. In Pune, HbA1c called 23.3 per cent of 116 young adults prediabetic where the glucose tolerance test called 7.8 per cent, in a group of whom a third were anaemic.
  • Shortened red cell survival lowers it: haemolysis, transfusion, erythropoiesis-stimulating agents, kidney failure and pregnancy. KDIGO says the measurement has low reliability on dialysis.
  • Haemoglobin variants interfere with some assays, and the HbA1c cannot be measured at all in HbSS or HbEE. HbE is common in the north-east of India and HbS in central India.
  • What to use instead: quality-controlled glucose profiles, fructosamine or total glycated haemoglobin, or the glucose management indicator and time in range from continuous monitoring. In pregnancy the estimated average glucose and the glucose management indicator must not be used.

6. The Indian Position

  • ICMR 2018: most patients below 7.0 per cent; tight control early and in the young; targets revised with complications and in the elderly; fasting 80 to 110 and 2-hour post-prandial 120 to 140 mg/dL.
  • RSSDI 2022: below 7.0 per cent; lower if quickly and safely reached without hypoglycaemia; higher where previous attempts produced unacceptable hypoglycaemia. No age-banded table.
  • ICMR-INDIAB-13, 2022: of 4834 adults with known diabetes across all states, 36.3 per cent had an HbA1c below 7.0; 7.7 per cent met the glycaemic, blood pressure and LDL targets together; 16.7 per cent self-monitored glucose, 36.9 per cent of those on insulin. The commonest departure from target in India is upward, not downward.
  • Anaemia is the Indian caveat. A raised HbA1c in a menstruating woman or a vegetarian with a low ferritin should be read beside a fasting and a post-prandial glucose before therapy is escalated.

7. Older Adults and the Floor

  • ADA 2026 Table 13.1: healthy, below 7.0 to 7.5 per cent, fasting 80 to 130; complex, below 8.0, fasting 90 to 150; very complex, no HbA1c target, fasting 100 to 180 and bedtime 110 to 200, to avoid hypoglycaemia and symptomatic hyperglycaemia.
  • Over-treatment is common and has a name. An HbA1c well below the goal on insulin or a sulfonylurea in a complex older adult is over-treatment, and the ADA recommends de-intensifying or switching to a class without hypoglycaemia. The ACP puts a number on it: consider de-intensifying below 6.5 per cent.
  • A low HbA1c on metformin alone is not over-treatment. NICE says to maintain it, and to think of a falling eGFR or weight loss as reasons a number drops.
  • The Endocrine Society asks that every outpatient regimen in a patient over 65 be designed to minimise hypoglycaemia, and that the target follow the overall health and whether a hypoglycaemia-causing drug is in use.

8. Pregnancy

  • Before conception: below 6.5 per cent (ADA 15.3), to reduce congenital anomalies, pre-eclampsia, macrosomia and preterm birth.
  • During pregnancy with pre-existing diabetes: below 6.0 per cent if it can be reached without significant hypoglycaemia, relaxed to below 7.0 if necessary (ADA 15.9). The HbA1c runs lower in pregnancy because red cell turnover rises, so the glucose profile is the primary instrument: fasting below 95, 1-hour below 140 or 2-hour below 120 mg/dL.
  • Gestational diabetes: MoHFW 2018 targets fasting below 95 and 2-hour post-prandial below 120 mg/dL. No guideline read gives an HbA1c target, and the tool does not invent one.
Abbreviations ACCORD (Action to Control Cardiovascular Risk in Diabetes) · ACP (American College of Physicians) · ADA (American Diabetes Association) · ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) · ASCVD (Atherosclerotic Cardiovascular Disease) · CGM (Continuous Glucose Monitoring) · CI (Confidence Interval) · CKD (Chronic Kidney Disease) · COPD (Chronic Obstructive Pulmonary Disease) · CVD (Cardiovascular Disease) · DCCT (Diabetes Control and Complications Trial) · DPP-4 (Dipeptidyl Peptidase-4) · eAG (Estimated Average Glucose) · EASD (European Association for the Study of Diabetes) · EDIC (Epidemiology of Diabetes Interventions and Complications) · eGFR (Estimated Glomerular Filtration Rate) · ESA (Erythropoiesis-Stimulating Agent) · GDM (Gestational Diabetes Mellitus) · GLP-1 (Glucagon-Like Peptide-1) · HbA1c (Glycated Haemoglobin) · HbD (Haemoglobin D) · HbE (Haemoglobin E) · HbEE (Homozygous Haemoglobin E) · HbS (Haemoglobin S) · HbSS (Homozygous Haemoglobin S, Sickle Cell Disease) · HIV (Human Immunodeficiency Virus) · HR (Hazard Ratio) · ICMR (Indian Council of Medical Research) · INDIAB (India Diabetes Study) · ISPAD (International Society for Pediatric and Adolescent Diabetes) · KDIGO (Kidney Disease: Improving Global Outcomes) · LDL (Low-Density Lipoprotein) · MoHFW (Ministry of Health and Family Welfare) · NGSP (National Glycohemoglobin Standardization Program) · NICE (National Institute for Health and Care Excellence) · RSSDI (Research Society for the Study of Diabetes in India) · SGLT2 (Sodium-Glucose Cotransporter-2) · UKPDS (United Kingdom Prospective Diabetes Study) · VADT (Veterans Affairs Diabetes Trial)
References
  1. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S132-S149.
  2. American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S277-S296.
  3. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S321-S338.
  4. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
  5. Indian Council of Medical Research. ICMR Guidelines for Management of Type 2 Diabetes 2018. New Delhi: ICMR; 2018.
  6. Research Society for the Study of Diabetes in India. RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022. Int J Diabetes Dev Ctries. 2022;42(Suppl 1):1-143.
  7. Ministry of Health and Family Welfare, Government of India. Diagnosis and Management of Gestational Diabetes Mellitus: Technical and Operational Guidelines. New Delhi; 2018.
  8. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline NG28. London: NICE; 2015, last updated 18 February 2026.
  9. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. NICE guideline NG17. London: NICE; 2015, last updated 17 August 2022.
  10. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127.
  11. Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018;168(8):569-576.
  12. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574.
  13. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154(8):554-559.
  14. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
  15. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149.
  16. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
  17. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016;39(5):686-693.
  18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
  19. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
  20. Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024;404(10448):145-155.
  21. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
  22. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
  23. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
  24. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
  25. Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up. N Engl J Med. 2019;380(23):2215-2224.
  26. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-1478.
  27. Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care. 2018;41(11):2275-2280.
  28. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-1334.
  29. Anjana RM, Unnikrishnan R, Deepa M, et al. Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study. Lancet Diabetes Endocrinol. 2022;10(6):430-441.
  30. Hardikar PS, Joshi SM, Bhat DS, et al. Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young indians partly explained by hematological factors and iron deficiency anemia. Diabetes Care. 2012;35(4):797-802.
  31. Rajagopal L, Ganapathy S, Arunachalam S, Raja V, Ramraj B. Does Iron Deficiency Anaemia and its Severity Influence HbA1C Level in Non Diabetics? An Analysis of 150 Cases. J Clin Diagn Res. 2017;11(2):EC13-EC15.
  32. de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23(8):1270-1276.
How to Cite This Tool

AMA Style:Umakanth S. Individualised HbA1c Target. Version 1. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/hba1c-target

Vancouver Style:Umakanth S. Individualised HbA1c Target [Internet]. Version 1. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/hba1c-target

Disclaimer and scope
Disclaimer: This decision-support system is written for healthcare professionals. It does not substitute clinical judgment, and the treating physician retains absolute responsibility for every diagnostic, dosing and therapeutic decision. The algorithms are built on the evidence as it stands, and the evidence moves. Verify the output against your current institutional protocol, and against the patient in front of you.
© 2026 MEDiscuss.org. All rights reserved. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Therapeutic & Management PathwaysCalculator
Specialties Internal Medicine, Endocrinology, Family Medicine, Geriatrics, Obstetrics, Nephrology

Revision date

Not recorded

Nobody has recorded when this content was last revised, so we cannot tell you how current it is. Check the doses and thresholds against current guidance before you use it.

How these tools are written and reviewed

Related Clinical Tools
Outpatient Diabetes PathwayInpatient Insulin ProtocolDiabetes Classification PathwayAnaemia Indices Calculator